The development of Paricam P-3005 is based on own expertise and research over a period of several years. It is protected by patent applications covering both, the compound itself (P-3005) and the oral formulation (thermogel). On this base we initiated research activities for a similar drug targeting the veterinary (canine/horse) market, which is also subject of a patent application. In addition, the development of OTC-products for the (oral) health-care market is kept on track for the proximate future.
Current status of our Intellectual Property Rights activities are as follows:
1. »Antisense drug against human intercellular adhesion molecule 1 (ICAM-1)«
Applicant: Universität zu Lübeck,
Inventors: Rosel Kretschmer-Kazemi Far, Georg Sczakiel
Status: European Patent Application in progress (exclusive and global agreement with University of Lübeck available).
Application no.: 19 153 666.3, filed on 25.01.2019
2. »Composition for administrating and releasing oligonucleotides«
Applicant: Breitenbronn Consulting
Inventors: Thomas Rupp, Wolfgang Nedbal, Georg Sczakiel
Status: European Patent Application in progress (own invention)
Application no.: 19 153 666.0 filed on 25.01.2019
3. »Antisense Drugs against Canine ICAM-1«
Applicant: Universität zu Lübeck
Inventors: Franziska Preuß, Rosel Kretschmer- Kazemi Far, Georg Sczakiel. Status: European Patent Application filed on 28. July 2017 (EP 17001305.6) (exclusive and global agreement with University of Lübeck available).